Peptide compounds, organized by evidence and regulatory status

Synthetic analog of the C-terminal fragment of human growth hormone studied for lipolytic activity in animal models. Failed to demonstrate efficacy...

Hexapeptide marketed as a topical SNAP-25 mimetic in cosmetic anti-wrinkle products.

Studied in animals for effects on angiogenesis, tendon/ligament cell migration, and nitric-oxide pathways. Mechanism in humans is not established.

Short-acting GHRH(1-29) analog without the DAC linker. Studied as a research-only compound.

GHRH analog conjugated to a drug-affinity-complex (DAC) extending half-life. Clinical development by ConjuChem was halted after a Phase II trial reported...

Long-acting amylin analog studied in Phase 3 development, typically in combination with semaglutide (CagriSema).

Mixture of low-molecular-weight peptides from porcine brain tissue. Studied in dementia and stroke; approved in some European and Asian countries. Not...

Synthetic angiotensin IV analog studied in rodent models of cognitive function. No published human clinical trial data.

Synthetic tetrapeptide studied by the Khavinson research group for putative telomerase activation and pineal-modulating effects. Independent replication is limited.

Senolytic peptide that disrupts FOXO4–p53 interaction; studied in aged mice for clearance of senescent cells. No human clinical data.

Studied for collagen synthesis, anti-inflammatory effects, and modulation of skin gene expression in topical/cosmetic use.

Synthetic ghrelin mimetic studied as a diagnostic tool for growth-hormone deficiency in some markets.

Ghrelin receptor agonist studied as a research compound for GH release; produces appetite stimulation in early trials.

Synthetic hexapeptide ghrelin mimetic studied for transient GH release and cardiovascular effects in animal models.

Mitochondrial-derived peptide studied in neuroprotection and metabolic regulation; early correlational human data.

Selective ghrelin receptor agonist that has been studied for transient growth-hormone release without significant cortisol or prolactin effects in early trials.

Preclinical studies suggest NF-κB pathway inhibition and reduced inflammatory cytokine output in mucosal models.

Endogenous neuropeptide that regulates GnRH pulse generation. Studied in Phase 2 trials for hypothalamic amenorrhea and male reproductive disorders.

Endogenous antimicrobial peptide with immunomodulatory and wound-healing activity studied in vitro and in animal models.

GLP-1 receptor agonist with an albumin-binding fatty acid linker. FDA-approved for type 2 diabetes and obesity.

Non-peptide oral ghrelin receptor agonist studied in trials for sarcopenia and frailty. Development was not pursued to approval.

Studied for metabolic regulation, insulin sensitivity, and exercise adaptation in animal models and early human pharmacokinetic studies.

Non-selective melanocortin receptor agonist studied for pigmentation effects. Not FDA-approved; carries documented safety concerns including hyperpigmentation, nausea, and case reports of...

Dipeptide racetam analog; approved in Russia for cognitive complaints. Limited Western-standard trial evidence.